keyword
MENU ▼
Read by QxMD icon Read
search

Asthma immunotherapy

keyword
https://www.readbyqxmd.com/read/27908569/effectiveness-of-immunotherapy-in-children-depends-on-place-of-living-a-pilot-study
#1
M Pawlowski, J Jerzynska, D Podlecka, W Stelmach, P Majak, I Stelmach
BACKGROUND: It is considered that farm areas protect young patients from allergy and asthma due to high exposure to endotoxins. Allergen immunotherapy (AIT) is the only treatment of allergy modifying the immune response with the potential to change the natural history of allergic diseases. It seems that studies evaluating the efficacy of immunotherapy in large cohorts of allergic patients living in farm areas are needed to understand the influence of environment on immune response during AIT...
November 28, 2016: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/27900996/suppression-of-immunotherapy-on-group-2-innate-lymphoid-cells-in-allergic-rhinitis
#2
Da-Chuan Fan, Xiang-Dong Wang, Cheng-Shuo Wang, Yang Wang, Fei-Fei Cao, Luo Zhang
BACKGROUND: Group 2 innate lymphoid cells (ILC2s) are regarded as a novel population of lineage-negative cells that induce innate Type 2 responses by producing the critical Th2-type cytokines interleukin (IL)-5 and IL-13. ILC2s as key players in the development of allergic rhinitis (AR) have been proved, however, the effect of subcutaneous immunotherapy (SCIT) with dermatophagoides pteronyssinus extract (Der p-SCIT) on ILC2s in AR patients is not clear. This study aimed to investigate the response of ILC2s of peripheral blood in house dust mites (HDM)-sensitized Chinese patients with AR who received SCIT with Der P extract...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27876361/beneficial-effects-of-galectin-9-on-allergen-specific-sublingual-immunotherapy-in-a-dermatophagoides-farinae-induced-mouse-model%C3%A2-of-chronic-asthma
#3
Masaki Ikeda, Shigeki Katoh, Hiroki Shimizu, Akira Hasegawa, Katsuyo Ohashi-Doi, Mikio Oka
BACKGROUND: Allergen-specific sublingual immunotherapy is a potential disease-modifying treatment for allergic asthma. Galectin-9 (Gal-9), a β-galactoside-binding protein with various biologic effects, acts as an immunomodulator in excessive immunologic reactions by expanding regulatory T cells (Treg) and enhancing transforming growth factor (TGF)-β signaling. We investigated the efficacy of sublingually administered Gal-9 as an adjuvant to a specific allergen in a Dermatophagoides farinae (Df)-induced mouse model of chronic asthma...
November 19, 2016: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/27875341/occupational-asthma-diagnostic-challenges-and-management-dilemmas
#4
Vrinda Trivedi, Dinesh R Apala, Vivek N Iyer
PURPOSE OF REVIEW: Work-related asthma encompasses both sensitizer-induced and irritant-induced occupational asthma as well as work-exacerbated asthma. This review summarizes current diagnostic and management strategies for occupational asthma. RECENT FINDINGS: Occupational asthma is the most common occupational lung disease in the industrialized world. Over 400 agents have been described to cause occupational asthma. Specific inhalation challenge is often considered the reference method for diagnosis of occupational asthma but specific inhalation challenge as well as other diagnostic tests all generate false positive or false negative results...
November 21, 2016: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/27871775/recombinant-proteins-of-helminths-with-immunoregulatory-properties-and-their-possible-therapeutic-use
#5
REVIEW
Leonardo Nascimento Santos, Luis Gustavo Carvalho Pacheco, Carina Silva Pinheiro, Neuza Maria Alcantara-Neves
The inverse relationship between helminth infections and the development of immune-mediated diseases is a cornerstone of the hygiene hypothesis and studies were carried out to elucidate the mechanisms by which helminth-derived molecules can suppress immunological disorders. These studies have fostered the idea that parasitic worms may be used as a promising therapeutic alternative for prevention and treatment of immune-mediated diseases. We discuss the current approaches for identification of helminth proteins with potential immunoregulatory properties, including the strategies based on high-throughput technologies...
November 18, 2016: Acta Tropica
https://www.readbyqxmd.com/read/27864091/diurnal-variations-in-subcutaneous-allergen-immunotherapy-reactions
#6
Aakash A Bavishi, Leslie C Grammer, Jacqueline Pongracic, Karen Rychlik, Rajesh Kumar, Phyllis Zee, Paul A Greenberger, Anna B Fishbein
BACKGROUND: Circadian rhythms underlie many immune responses and allergic diseases. Subcutaneous immunotherapy (SCIT) can result in adverse reactions; however, it is unclear whether such reactions have a diurnal pattern. OBJECTIVE: To assess whether the timing of SCIT affects the rate of adverse reactions. METHODS: This study was a retrospective medical record review of adult patients (n = 289) who received SCIT at the Northwestern Medical Faculty Foundation, Chicago, Illinois, during a 10-year period (2004-2014)...
November 15, 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27852426/comparing-the-compliance-to-a-short-schedule-of-subcutaneous-immunotherapy-and-to-sublingual-immunotherapy-during-three-years-of-treatment
#7
G Manzotti, G G Riario-Sforza, M Dimatteo, C Scolari, E Makri, C Incorvaia
BACKGROUND: Allergen immunotherapy (AIT) in its two forms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) is an effective treatment of respiratory allergy, but is particularly concerned by the issue of compliance. OBJECTIVE: We aimed a real-life study at evaluating the compliance to SLIT and to SCIT administered by a short-course of four injections during a 3-year period of observation. METHODS: A group of 145 patients (79 males, 66 females, age ranging from 14 to 69 years), suffering from pollen-induced rhino-conjunctivitis with or without asthma, were included in the study...
November 2016: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27820664/compliance-with-allergen-immunotherapy-and-factors-affecting-compliance-among-patients-with-respiratory-allergies
#8
Fardous Musa, Mona Al-Ahmad, Nermina Arifhodzic, Waleed Al-Herz
BACKGROUND: Allergen-specific immunotherapy (AIT) is safe and effective for the treatment of allergic rhinitis and allergic asthma. However, patient non-compliance is a major barrier to achieving optimal outcomes. OBJECTIVE: To determine the level of compliance among patients using AIT and to identify factors associated with non-compliance. METHODS: A retrospective analysis using questionnaires was conducted to study compliance among 236 patients with allergic rhinitis with or without asthma who began AIT in 2009 or 2010...
November 7, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27817798/advances-in-rhinitis-and-rhinosinusitis-in-2015
#9
REVIEW
Claus Bachert, Elien Gevaert
The last year has seen great progress in the understanding of upper airway disease and in its management. For allergic rhinitis, authors focused on the prediction of and effect on the natural course of disease. New evidence was published for the disease-modifying effect of allergen immunotherapy in terms of avoidance of new sensitizations and prevention of asthma in either randomized or real-life studies. Specifically, for patients with house dust mite allergies, which are often underestimated and difficult to diagnose, the efficacy of SQ house dust mite sublingual immunotherapy tablets has been demonstrated in patients with allergic rhinitis and asthma...
November 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27798419/novel-targets-of-omalizumab-in-asthma
#10
Caroline Sattler, Gilles Garcia, Marc Humbert
PURPOSE OF REVIEW: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody approved in the US for moderate to severe persistent allergic asthma (severe persistent asthma in the European Union), uncontrolled despite treatment with inhaled corticosteroids and long-acting beta2 agonists. It reduces asthma exacerbations, symptoms, oral corticosteroid doses, and improves quality of life. RECENT FINDINGS: Omalizumab may have an antiviral effect when used as a preventive therapy for fall exacerbations in children and teenagers...
January 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/27795212/-economic-consequences-in-real-life-of-allergen-immunotherapy-in-asthma-rhinitis-and-dermatitis
#11
Jorge Sánchez, Andrés Sánchez, Ricardo Cardona
BACKGROUND: Allergen immunotherapy has proved effective in the treatment of various allergies, but whether the clinical benefits outweigh the economic costs has been little evaluated. OBJECTIVE: To explore the economic consequences of immunotherapy in asthma, rhinitis and dermatitis. METHODS: Descriptive study. Patients with at least 18 months' follow-up were selected, whose medical history allowed evaluation of drugs received, manner of use, check-ups, treatment changes, reasons for these, and so on...
October 2016: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/27788885/comparison-of-systemic-reactions-in-rush-cluster-and-standard-build-aeroallergen-immunotherapy
#12
Andrew W Winslow, Joseph C Turbyville, J Wesley Sublett, James L Sublett, Stephen J Pollard
BACKGROUND: Given the choice of standard, cluster, and rush build-up for aeroallergen immunotherapy, standard-build immunotherapy has generally been preferred because of a perceived high rate of systemic reactions (SRs) associated with cluster and rush immunotherapy. OBJECTIVE: To characterize the incidence of SRs during standard, cluster, and rush build-up immunotherapy in an allergy practice during a 5-year period. METHODS: A retrospective review was conducted among patients receiving standard-build, 8- to 10-step cluster, or 2-day rush immunotherapy from January 1, 2010, through December 31, 2014, at Family Allergy & Asthma clinics in Louisville, Kentucky...
November 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27773851/intradermal-grass-pollen-allergen-immunotherapy-for-seasonal-allergy-a-randomized-controlled-trial
#13
Anna Slovick, Abdel Douiri, Rachel Muir, Andrea Guerra, Konstantinos Tsioulos, Evie Hay, Emily P S Lam, Joanna Kelly, Janet L Peacock, Sun Ying, Mohamed H Shamji, David J Cousins, Stephen R Durham, Stephen J Till
BACKGROUND: Repeated low dose grass pollen intradermal allergen injection suppresses allergen-induced cutaneous late phase responses, comparable with conventional subcutaneous and sublingual immunotherapy. OBJECTIVE: To evaluate the efficacy and safety of grass pollen intradermal immunotherapy in the treatment of allergic rhinitis. METHODS: We randomly assigned 93 adults with grass pollen allergic rhinitis to receive 7 pre-seasonal intradermal allergen injections (containing 7 nanograms of Phl p 5 major allergen) or histamine control...
October 20, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27731323/the-regulatory-dendritic-cell-marker-c1q-is-a-potent-inhibitor-of-allergic-inflammation
#14
L Mascarell, S Airouche, N Berjont, C Gary, C Gueguen, G Fourcade, B Bellier, D Togbe, B Ryffel, D Klatzmann, V Baron-Bodo, P Moingeon
The complement subunit C1q was recently identified as a marker for monocyte-derived regulatory dendritic cells supporting the differentiation of interleukin (IL)-10-secreting CD4(+) T cells with a suppressive activity. Furthermore, C1q expression is upregulated in peripheral blood mononuclear cells of allergic patients in the course of successful allergen immunotherapy. Herein, we investigated a potential direct role of C1q in downregulating allergic inflammation. In mice with ovalbumin (OVA) or birch pollen (BP)-induced allergic asthma, C1q is as efficacious as dexamethasone to reduce both airway hyperresponsiveness (AHR), eosinophil, and ILC2 infiltrates in bronchoalveolar lavages, as well as allergen-specific T helper 2 cells in the lungs...
October 12, 2016: Mucosal Immunology
https://www.readbyqxmd.com/read/27718250/european-survey-on-adverse-systemic-reactions-in-allergen-immunotherapy-eassi-a-real-life-clinical-assessment
#15
Moisés A Calderón, Carmen Vidal, Pablo Rodríguez Del Río, Jocelyne Just, Oliver Pfaar, Ana I Tabar, Inmaculada Sánchez-Machín, Petra Bubel, Jesus Borja, Peter Eberle, Rainer Reiber, Michel Bouvier, Alain Lepelliez, Ludger Klimek, Pascal Demoly
BACKGROUND: Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (AIT) are scarce. METHODS: A prospective, longitudinal, web-based survey of "real-life" respiratory allergen immunotherapy (AIT) clinical practice was conducted in France, Germany and Spain. SRs were recorded and coded according to the Medical Dictionary for Regulatory Activities (MedDRA) and risk factors associated with SRs were identified. RESULTS: A total of 4,316 patients (corresponding to 4,363 ongoing courses of AIT) were included...
October 8, 2016: Allergy
https://www.readbyqxmd.com/read/27678500/applications-and-mechanisms-of-immunotherapy-in-allergic-rhinitis-and-asthma
#16
Jasper H Kappen, Stephen R Durham, Hans In 't Veen, Mohamed H Shamji
Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such as mast cells, eosinophils and basophils in target organs. Furthermore, AIT down-regulates type 2 innate lymphoid cells and allergen-specific type 2 T-helper (Th2) cells. The immunologic tolerant state following AIT is associated with the induction of distinct phenotypes of regulatory T-cells (T-regs) including interleukin (IL)-10-, IL-35- and transforming growth factor (TGF)-β- producing T-regs and FoxP3(+) T-regs...
September 27, 2016: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/27637414/the-european-survey-on-adverse-systemic-reactions-in-allergen-immunotherapy-eassi-a-paediatric-assessment
#17
Pablo Rodríguez Del Río, Carmen Vidal, Jocelyne Just, Ana I Tabar, Inmaculada Sanchez-Machin, Peter Eberle, Jesus Borja, Petra Bubel, Oliver Pfaar, Pascal Demoly, Moises A Calderón
BACKGROUND: Safety data on "real-life" allergen immunotherapy (AIT) in children and adolescents is usually extrapolated from studies in adults. METHODS: Patients aged 18 or under initiating aeroallergen AIT were evaluated in a prospective European survey. Patient profiles and systemic reactions (SRs) were recorded. Descriptive, univariate and multivariate analyses were used to identify risk factors for SRs. RESULTS: A total of 1,563 patients (mean±SD age: 11...
September 17, 2016: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/27637121/medications-for-chronic-asthma
#18
Nathan P Falk, Scott W Hughes, Blake C Rodgers
Chronic asthma is a major health concern for children and adults worldwide. The goal of treatment is to prevent symptoms by reducing airway inflammation and hyperreactivity. Step-up therapy for symptom control involves initiation with low-dose treatment and increasing intensity at subsequent visits if control is not achieved. Step-down therapy starts with a high-dose regimen, reducing intensity as control is achieved. Multiple randomized controlled trials have shown that inhaled corticosteroids are the most effective monotherapy...
September 15, 2016: American Family Physician
https://www.readbyqxmd.com/read/27632814/300-ir-hdm-tablet-a-sublingual-immunotherapy-tablet-for-the-treatment-of-house-dust-mite-associated-allergic-rhinitis
#19
Pascal Demoly, Yoshitaka Okamoto, William H Yang, Philippe Devillier, Karl-Christian Bergmann
INTRODUCTION: The once-daily 300 index of reactivity (IR) house dust mite (HDM) tablet (Actair®; Stallergenes Greer, Antony, France/Shionogi & Co. Ltd., Osaka, Japan) is the first sublingual immunotherapy (SLIT) tablet to be approved for the treatment of HDM-induced allergic rhinitis. AREAS COVERED: This drug profile reviews the current body of evidence on the efficacy, safety and tolerability of the 300 IR HDM tablet, its pharmacodynamics, and its role in clinical practice...
September 15, 2016: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/27620194/mk-8237-a-house-dust-mite-vaccine-for-treating-allergic-rhinitis-asthma-and-atopic-dermatitis
#20
Matteo Ferrando, Diego Bagnasco, Giovanni Passalacqua, Gilda Varricchi, Giorgio Walter Canonica
INTRODUCTION: Since its introduction in clinical practice one century ago for the treatment of respiratory allergic diseases, allergen-specific immunotherapy (AIT) has exhibited a relevant clinical efficacy that was subsequently confirmed in controlled trials. Thus, AIT has been accepted worldwide, as testified by guidelines and international documents. AIT is considered pivotal in the management of allergic rhinitis with or without conjunctivitis and with or without asthma. These conditions, in addition to hymenoptera venom allergy, currently are the accepted indications...
November 2016: Expert Opinion on Biological Therapy
keyword
keyword
15390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"